AU2010322454B2 - Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells - Google Patents

Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells Download PDF

Info

Publication number
AU2010322454B2
AU2010322454B2 AU2010322454A AU2010322454A AU2010322454B2 AU 2010322454 B2 AU2010322454 B2 AU 2010322454B2 AU 2010322454 A AU2010322454 A AU 2010322454A AU 2010322454 A AU2010322454 A AU 2010322454A AU 2010322454 B2 AU2010322454 B2 AU 2010322454B2
Authority
AU
Australia
Prior art keywords
polysaccharide
und
coli
galnac
oligo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010322454A
Other languages
English (en)
Other versions
AU2010322454A1 (en
Inventor
Michael Wacker
Charles Waechter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2010322454A1 publication Critical patent/AU2010322454A1/en
Application granted granted Critical
Publication of AU2010322454B2 publication Critical patent/AU2010322454B2/en
Assigned to GLYCOVAXYN AG reassignment GLYCOVAXYN AG Amend patent request/document other than specification (104) Assignors: GLYCOVAXYN AG
Assigned to GLAXOSMITHKLINE BIOLOGICALS S.A. reassignment GLAXOSMITHKLINE BIOLOGICALS S.A. Request for Assignment Assignors: GLYCOVAXYN AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AU2010322454A 2009-11-19 2010-11-16 Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells Active AU2010322454B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27293109P 2009-11-19 2009-11-19
US61/272,931 2009-11-19
PCT/US2010/002980 WO2011062615A1 (en) 2009-11-19 2010-11-16 Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells

Publications (2)

Publication Number Publication Date
AU2010322454A1 AU2010322454A1 (en) 2012-06-07
AU2010322454B2 true AU2010322454B2 (en) 2016-05-19

Family

ID=44059888

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010322454A Active AU2010322454B2 (en) 2009-11-19 2010-11-16 Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells

Country Status (20)

Country Link
US (2) US8846342B2 (enExample)
EP (1) EP2501406B8 (enExample)
JP (2) JP5968784B2 (enExample)
KR (1) KR101855380B1 (enExample)
CN (1) CN102724997B (enExample)
AU (1) AU2010322454B2 (enExample)
CA (1) CA2780487C (enExample)
CY (1) CY1119995T1 (enExample)
DK (1) DK2501406T3 (enExample)
ES (1) ES2660227T3 (enExample)
HR (1) HRP20180338T1 (enExample)
HU (1) HUE038456T2 (enExample)
IL (1) IL219733A (enExample)
LT (1) LT2501406T (enExample)
NO (1) NO2501406T3 (enExample)
PL (1) PL2501406T3 (enExample)
PT (1) PT2501406T (enExample)
SI (1) SI2501406T1 (enExample)
TR (1) TR201803015T4 (enExample)
WO (1) WO2011062615A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1481057T3 (da) * 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
NO2501406T3 (enExample) * 2009-11-19 2018-05-19
EP2742355B1 (en) * 2011-08-12 2018-12-19 The Governors of the University of Alberta Method of diagnosing bacterial infections using bacterial glycoproteins
CA2879272A1 (en) 2012-07-16 2014-01-23 Robert G.K. DONALD Saccharides and uses thereof
US20150353940A1 (en) 2013-08-05 2015-12-10 Absci, Llc Vectors for use in an inducible coexpression system
EP2724730A1 (en) 2012-10-29 2014-04-30 Institut Pasteur Glycoconjugates and their use as potential vaccines against infection by Shigella Flexneri
HUE038915T2 (hu) 2013-01-17 2018-12-28 Arsanis Biosciences Gmbh MDR E. colira fajlagos antitest
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
BR112016007727A8 (pt) * 2013-10-11 2018-01-30 Glycovaxyn Ag célula hospedeira, e, método para produzir uma proteína n-glicosilada.
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
MX378857B (es) * 2014-04-17 2025-03-10 Glaxosmithkline Biologicals Sa Celulas huespedes modificadas y usos de las mismas.
KR101629656B1 (ko) * 2014-10-24 2016-06-14 충남대학교산학협력단 면역증강효과를 갖는 수용성 다당체 및 이를 함유하는 조성물
SI3240895T1 (sl) * 2014-12-30 2022-04-29 Glaxosmithkline Biologicals S.A. Sestavki in postopki za glikozilacijo proteinov
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
EP3384018A1 (en) 2015-11-30 2018-10-10 Limmatech Biologics AG Methods of producing glycosylated proteins
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
JP7551618B2 (ja) 2018-12-12 2024-09-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
CA3185719A1 (en) 2020-06-18 2021-12-23 Glaxosmithkline Biologicals Sa Shigella-tetravalent (shigella4v) bioconjugate
US20230226175A1 (en) 2020-06-25 2023-07-20 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
PE20231385A1 (es) 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas
CN112877246B (zh) * 2021-02-23 2022-01-18 山东省滨州畜牧兽医研究院 一种高效制备霍乱弧菌菌影的方法
CN115747239A (zh) * 2021-09-03 2023-03-07 上海交通大学 用于表达黏蛋白型o-糖基化蛋白的原核载体和系统、黏蛋白型o-糖基化蛋白的制备方法
EP4452308A1 (en) 2021-12-22 2024-10-30 GlaxoSmithKline Biologicals S.A. Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089396A2 (en) * 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugation of polypeptides using oligosaccharyltransferases
WO2009104074A2 (en) * 2008-02-20 2009-08-27 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60142915A (ja) * 1983-12-28 1985-07-29 Lion Corp 口腔用組成物
EP0170204B1 (de) 1984-08-01 1991-09-25 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen
US5242809A (en) * 1986-02-28 1993-09-07 Smithkline Beecham Corporation Gal operon of streptomyces
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
US5665559A (en) * 1989-05-18 1997-09-09 The United States Of America As Represented By The Secretary Of The Navy Production of monoclonal antibodies to bacteroides gingivalis by hybridoma BGII, VF9/2D
US5280113A (en) * 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
AU6663294A (en) 1993-05-14 1994-12-12 Upjohn Company, The Cloned dna encoding a udp-galnac:polypeptide,n-acetylgalactos aminyltransferase
US6365723B1 (en) * 1998-12-04 2002-04-02 Wisconsin Alumni Research Foundation Sequences of E. coli O157
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
EP1399538A2 (en) 1999-03-02 2004-03-24 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
NZ522320A (en) 2000-05-12 2007-03-30 Neose Technologies Inc In vitro modification of glycosylation patterns of recombinant glycopeptides
EP2028275A3 (en) 2000-06-30 2009-05-06 VIB vzw Protein glycosylation modification in pichia pastoris
US20040067557A1 (en) * 2000-12-21 2004-04-08 Tetsuo Endo Process for producing udp-n-acetylgalactosamine and sacciiaride containing n-acetylgalactosamine
US20020132320A1 (en) * 2001-01-10 2002-09-19 Wang Peng George Glycoconjugate synthesis using a pathway-engineered organism
US20020150968A1 (en) * 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
US6696814B2 (en) 2001-07-09 2004-02-24 Tyco Electronics Corporation Microprocessor for controlling the speed and frequency of a motor shaft in a power tool
US7265085B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7541043B2 (en) * 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
JP4727927B2 (ja) * 2002-03-07 2011-07-20 アイトゲネシシェ・テッヒニシェ・ホーホシューレ・チューリッヒ 原核宿主における組換えグリコシル化タンパク質産生のためのシステムおよび方法
DK1481057T3 (da) 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
CN1671722A (zh) 2002-08-01 2005-09-21 加拿大国家研究院 弯曲菌的聚糖和糖肽
EP2657251B1 (en) 2004-05-24 2018-03-21 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Live, oral vaccine for protection against Shigella dysenteriae serotype 1
JP5235657B2 (ja) * 2005-03-24 2013-07-10 バイオジェネリックス ゲーエムベーハー 原核生物における可溶性活性真核生物グリコシルトランスフェラーゼの発現
ES2535084T3 (es) 2005-05-11 2015-05-05 Eth Zurich Proteínas N-glicosiladas recombinantes procedentes de células procariotas
US20070202578A1 (en) * 2005-08-26 2007-08-30 Centre National De La Recherche Scientifique (Cnrs) Production of globosides oligosaccharides using metabolically engineered microorganisms
WO2009089154A2 (en) * 2008-01-03 2009-07-16 Cornell Research Foundation, Inc. Glycosylated protein expression in prokaryotes
CN102365359B (zh) * 2009-03-27 2014-10-29 瑞士联邦苏黎世技术大学 呈递空肠弯曲杆菌n-聚糖或其衍生物的肠沙门氏菌
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
NO2501406T3 (enExample) * 2009-11-19 2018-05-19
CA2789505C (en) * 2010-02-11 2017-12-05 The Governors Of The University Of Alberta N-linked glycan compounds
WO2011138361A1 (en) * 2010-05-06 2011-11-10 Glycovaxyn Capsular gram-positive bacteria bioconjugate vaccines
WO2012027850A1 (en) * 2010-09-03 2012-03-08 Christine Szymanski Peptide containing multiple n-linked glycosylation sequons
WO2013019625A2 (en) * 2011-07-29 2013-02-07 The University Of Wyoming Methods of using a bacterial glcnac-6-p 2'-epimerase to promote sialylation of glycoconjugates
CA2847621A1 (en) * 2011-09-06 2013-03-14 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
EP2917351B1 (en) * 2012-11-07 2018-12-19 GlaxoSmithKline Biologicals S.A. Production of recombinant vaccine in e. coli by enzymatic conjugation
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089396A2 (en) * 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugation of polypeptides using oligosaccharyltransferases
WO2009104074A2 (en) * 2008-02-20 2009-08-27 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells

Also Published As

Publication number Publication date
EP2501406A1 (en) 2012-09-26
IL219733A (en) 2017-08-31
CA2780487C (en) 2019-05-21
DK2501406T3 (en) 2018-02-26
JP2013511520A (ja) 2013-04-04
HUE038456T2 (hu) 2018-10-29
JP5968784B2 (ja) 2016-08-10
ES2660227T3 (es) 2018-03-21
EP2501406B8 (en) 2018-01-24
EP2501406B1 (en) 2017-12-20
US20150190492A1 (en) 2015-07-09
CA2780487A1 (en) 2011-05-26
LT2501406T (lt) 2018-03-26
KR101855380B1 (ko) 2018-05-08
JP2017018098A (ja) 2017-01-26
NO2501406T3 (enExample) 2018-05-19
SI2501406T1 (en) 2018-03-30
HRP20180338T1 (hr) 2018-04-06
US9764018B2 (en) 2017-09-19
AU2010322454A1 (en) 2012-06-07
TR201803015T4 (tr) 2018-03-21
CN102724997A (zh) 2012-10-10
IL219733A0 (en) 2012-07-31
US8846342B2 (en) 2014-09-30
EP2501406A4 (en) 2013-04-24
WO2011062615A1 (en) 2011-05-26
CY1119995T1 (el) 2018-12-12
KR20120102086A (ko) 2012-09-17
PT2501406T (pt) 2018-02-21
US20130028926A1 (en) 2013-01-31
CN102724997B (zh) 2016-09-21
PL2501406T3 (pl) 2018-05-30

Similar Documents

Publication Publication Date Title
US9764018B2 (en) Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
Price et al. Glycoengineered outer membrane vesicles: a novel platform for bacterial vaccines
CN103079591B (zh) 荚膜革兰氏阳性细菌生物缀合物疫苗
AU2009215341B2 (en) Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
US20150238596A1 (en) Bioconjugates comprising modified antigens and uses thereof
EA015833B1 (ru) Иммуногенная композиция
KR20230043157A (ko) 다가 백신 조성물 및 이의 용도
WO2024175620A1 (en) Immunogenic composition
EP1747262B1 (en) Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates
CN101014698A (zh) 作为多种疫苗候选物的保守性内核脂多糖表位
Compostella et al. Antibacterial Carbohydrate Vaccines
Adamo et al. Carbohydrate-based Therapeutics
US20250381257A1 (en) Vaccine
Palmieri Investigazione di tecnologie alternative per lo sviluppo di vaccini basati su polisaccaridi
Stevenson Engineering Bacterial Glycobiology for the Creation of Glycoconjugate Vaccines
Chen Glycoengineered vesicle vaccines against bacterial pathogens
Chen GLYCOENGINEERED VESICLE VACCINES AGAINST BACTERIAL PATHOGENS
Omari Synthesis of Campylobacter and Shigella glycoconjugate Vaccines
Corradin et al. Michael Wetter, Michael Kowarik, Michael Steffen, Paula Carranza

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A.

Free format text: FORMER OWNER(S): GLYCOVAXYN AG